Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A
IRWD
Get informed when a big investor buys or sells
+ FollowMarket Cap$679.85M
Close$
$11.86
178.3% upside
Current Fair Value
178.3% upsideUndervalued by 178.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $679.85 Million |
|---|---|
| Enterprise Value | $612.59 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.15 |
| Beta | 0.21 |
| Outstanding Shares | 165,454,839 |
Return
| Return on Equity | -167.25% |
|---|---|
| Return on Assets | 94.93% |
| Return on Invested Capital | 94.46% |
Valuation & Multiples
| P/E Ratio | 5.19 |
|---|---|
| PEG | 4.42 |
| Price to Sales | 2.13 |
| Price to Book Ratio | -4.26 |
| Enterprise Value to Revenue | 1.57 |
| Enterprise Value to EBIT | 2.57 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | -0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$0.32
Average shareholder expectationRevenue Estimate
$114.84 M
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$0.30
Average shareholder expectationRevenue Estimate
$119.99 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.0730▲ 203.81% |
|---|---|
| Total Calls | 250,700▼ 97.82% |
| Total Puts | 519,700▲ 29.96% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 100.25%▲ 0.69% |
|---|---|
| Total Invested | $691.96M▲ 22.08% |
| Investors Holding | 220▼ 15.00% |
ESG Score
No data
About Ironwood Pharmaceuticals Inc
CEO: Mark Mallon